Latest news for Roth CH Acquisition (NASDAQ:ROCL) Stock

Roth CH Acquisition V Co is a blank check company.

Roth CH Acquisition V Co

ROYAL OLYMPIC CRUISE LINE by Royal Olympic Cruise Lines, Inc.

Royal Olympic Cruise Lines Inc

Payable On August 19 To Unitholders Of Record On August 9

News

Energy Transfer Increases Quarterly Cash Distribution To $0.32 Per Unit For Q2 2024, Up 3.2% From Last Year

WIIM

Norfolk Southern shares are trading higher after the company reported better-than-expected Q2 earnings results.

Small Cap Consumer Research analyst Eric Beder reiterates Vince Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VNCE#NYSE">VNCE</a>) with a Buy and maintains $3 price target.

Price Target

Reiteration

Analyst Ratings

VNCE

Small Cap Consumer Research Reiterates Buy on Vince Holding, Maintains $3 Price Target

Q3 2024 Outlook – Weyerhaeuser anticipates third quarter earnings will be approximately $10 million lower than the second quarter and Adjusted EBITDA will be approximately $30 million lower than the second quarter due to the timing and mix of real estate sales. The company now expects full year 2024 Adjusted EBITDA to be approximately $330 million, a $10 million increase from prior outlook, and continues to expect basis as a percentage of real estate sales to be 35 to 45 percent for the full year.
Q3 2024 Outlook – Weyerhaeuser anticipates third quarter earnings before special items and Adjusted EBITDA will be lower than the second quarter, excluding the effect of changes in average sales realizations for lumber and oriented strand board. For lumber, the company expects lower sales volumes, slightly lower log costs, and higher unit manufacturing costs. For oriented strand board, the company anticipates comparable sales volumes, slightly higher fiber costs, and moderately higher unit manufacturing costs. For engineered wood products, the company expects comparable sales volumes, lower raw material costs, and moderately lower sales realizations, primarily for plywood and medium density fiberboard. For distribution, the company anticipates slightly lower results compared to the second quarter.

Guidance

Weyerhaeuser Sees Q3 Earnings ~$10M Lower Than Q2, Adj. EBITDA Will Be ~$30M Lower Than Q2 Due To Timing And Mix Of Real Estate Sales; Sees FY24 Adj. EBITDA ~$330M, $10M Increase From Prior Outlook, Expect Basis As A Percentage Of Real Estate Sales To Be 35%-45%

Associated Banc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASB#NYSE">ASB</a>) reported quarterly earnings of $0.52 per share which met the analyst consensus estimate. This is a 7.14 percent decrease over earnings of $0.56 per share from the same period last year. The company reported quarterly sales of $321.752 million which missed the analyst consensus estimate of $330.872 million by 2.76 percent. This is a 0.53 percent decrease over sales of $323.460 million the same period last year.

Earnings

Earnings Misses

Associated Banc Q2 2024 GAAP EPS $0.52, Inline, Sales $321.752M Miss $330.872M Estimate

DXCM

Dexcom Sees FY24 Revenue $4.00B-$4.05B vs $4.33B Est.

Ultra Clean Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UCTT#NASDAQ">UCTT</a>) reported quarterly earnings of $0.32 per share which beat the analyst consensus estimate of $0.26 by 23.08 percent. This is a 100 percent increase over earnings of $0.16 per share from the same period last year. The company reported quarterly sales of $516.100 million which beat the analyst consensus estimate of $490.064 million by 5.31 percent. This is a 22.44 percent increase over sales of $421.500 million the same period last year.

Earnings Beats

UCTT

Ultra Clean Hldgs Q2 2024 Adj EPS $0.32 Beats $0.26 Estimate, Sales $516.100M Beat $490.064M Estimate

Jefferies analyst Randal Konik reiterates Lululemon Athletica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LULU#NASDAQ">LULU</a>) with a Underperform and maintains $220 price target.

LULU

Jefferies Reiterates Underperform on Lululemon Athletica, Maintains $220 Price Target

DexCom Sees Q3 2024 Revenue $975M-$1.00B vs $1.15B Est.

SSNC

SS&C Technologies Revises FY24 Adjusted Revenue Forecast From ~$5.694B – $5.854B To $5.706B – $5.866B (Est $5.78B),  Adjusted EPS From $4.93 – $5.17 To $4.98 – $5.22 (Est $5.11)

Horace Mann Educators Expects FY 2024 Core EPS Between $2.40 - $2.70, With Q2 Core EPS Of $0.18- $0.20; Confidence In Achieving 10% Return On Equity By 2025 Amid Profitability Restoration And Sales Growth

Buybacks

The Hartford Board Authorizes New $3B Buyback Program

Weyerhaeuser (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WY#NYSE">WY</a>) reported quarterly earnings of $0.21 per share which met the analyst consensus estimate. This is a 34.38 percent decrease over earnings of $0.32 per share from the same period last year. The company reported quarterly sales of $1.94 billion which missed the analyst consensus estimate of $1.95 billion by 0.62 percent. This is a 2.90 percent decrease over sales of $2.00 billion the same period last year.

Weyerhaeuser Q2 Adj $0.21, Inline, Sales $1.94B Miss $1.95B Estimate

Payable Sept. 26 To Shareholders Of Record As Of Aug. 27

Dividends

VOYA

Voya Financial Announces 12.5% Increase In Dividend From $0.40 To $0.45 Per Share For Q3 2024

Novo Nordisk A/S Common Stock (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) experienced a notable decline on Thursday. This movement follows a significant announcement from <a href="https://www.benzinga.com/news/24/07/39966690/viking-therapeutics-stock-surges-as-company-advances-weight-loss-drug-to-late-stage-trial-what-inves">competitor Viking Therapeutics Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>).
What To Know: Viking Therapeutics announced the company has advanced its obesity candidate VK2735 into late-stage trials. This <a href="https://www.benzinga.com/news/24/07/39966690/viking-therapeutics-stock-surges-as-company-advances-weight-loss-drug-to-late-stage-trial-what-inves">advancement has intensified competition</a> in the GLP-1 market, which is currently led by Novo Nordisk and Eli Lilly corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>).
Viking Therapeutics&#8217; report of promising results for its obesity drug, showing up to a 15% reduction in body weight over 13 weeks, has pressured Novo Nordisk. This development challenges Novo Nordisk's leading position in the obesity treatment market.
What Else: The options market for Novo Nordisk has shown a predominantly bearish sentiment recently. Out of eight detected trades, 62% were bearish, including three put options totaling $155,555 and five call options amounting to $255,360.
Novo Nordisk&#8217;s trading volume reached 1,568,565, with the stock nearing oversold conditions according to RSI indicators. The company's next earnings report is expected in 13 days. 
Analyst Opinions: Cantor Fitzgerald recently downgraded Novo Nordisk to &#8216;Overweight&#8217; but maintained a price target of $160.
NVO Price Action: Novo Nordisk shares were down by 2.88% at $127.86 according to<a href="https://pro.benzinga.com/dashboard"> Benzinga Pro.</a>
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/pro/checkout/benzinga-pro-essential-2024?utm_source=BZprocontent072524&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="1024" height="540" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/25160653/NVO-1024x540.png" alt="" class="wp-image-457886" style="width:425px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/25160653/NVO-1024x540.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/25160653/NVO-300x158.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/25160653/NVO-768x405.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/25160653/NVO.png 1077w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
See Also:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/07/39966014/can-independent-bank-corp-run-higher-on-rising-earnings-estimates">Can Independent Bank Corp. Run Higher on Rising Earnings Estimates?</a></li>
</ul>
Photo via Shutterstock.

Health Care

After-Hours Center

Movers

VKTX

Novo Nordisk Shares Decline Amid Competitive Pressure

SS&C Sees FY24 Revenue $5.7B-$5.86B Vs $6.03B Estimate; Sees Adj. EPS $4.98-$5.22 Vs $5.64 Estimate

DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) reported quarterly earnings of $0.43 per share which beat the analyst consensus estimate of $0.39 by 10.26 percent. The company reported quarterly sales of $1.004 billion which missed the analyst consensus estimate of $1.036 billion by 3.13 percent. This is a 15.23 percent increase over sales of $871.300 million the same period last year.

DexCom Q2 2024 Adj EPS $0.43 Beats $0.39 Estimate, Sales $1.004B Miss $1.036B Estimate

Kinsale Cap Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KNSL#NYSE">KNSL</a>) reported quarterly earnings of $3.97 per share which beat the analyst consensus estimate of $3.53 by 12.46 percent. The company reported quarterly sales of $384.55 million which beat the analyst consensus estimate of $372.57 million by 3.22 percent. This is a 30.02 percent increase over sales of $295.77 million the same period last year.

KNSL

Kinsale Cap Gr Q2 2024 Adj EPS $3.97 Beats $3.53 Estimate, Sales $384.55M Beat $372.57M Estimate

Data reviewed complies with standards that would be&nbsp;used to evaluate an EU Marketing Authorization Application
PLYMOUTH MEETING, Pa., July 25, 2024 /PRNewswire/ -- INOVIO (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>), a biotechnology company focused on developing and commercializing DNA medicines to&nbsp;help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that&nbsp;the European Medicines Agency's Committee for Advanced Therapies (CAT) has certified the quality and non-clinical data for INO-3107, INOVIO's lead candidate&nbsp;for&nbsp;the treatment of Recurrent Respiratory Papillomatosis (RRP). The certification confirms that INOVIO's chemistry, manufacturing and controls (CMC) data and nonclinical results available to date comply with the scientific and technical standards that would be used for evaluating a European Marketing Authorization Application.

Biotech

General

Inovio Receives Advanced Therapy Medicinal Product Certificate From EMA For Quality And Non-Clinical Data For Lead Candidate INO-3107

Universal Logistics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULH#NASDAQ">ULH</a>) reported quarterly earnings of $1.17 per share which beat the analyst consensus estimate of $1.14 by 2.63 percent. The company reported quarterly sales of $462.164 million which beat the analyst consensus estimate of $461.600 million by 0.12 percent. This is a 12.02 percent increase over sales of $412.572 million the same period last year.

Universal Logistics Hldgs Q2 2024 GAAP EPS $1.17 Beats $1.14 Estimate, Sales $462.164M Beat $461.600M Estimate

Stronghold Digital Mining, Bit Origin among top financial movers

New Era Helium Corp to list on NASDAQ through merger with Roth CH Acquisition

BTOG

HNRA

PACI

PAPL

RMCO

ROCL

SDIG

SNTG

Press Releases

Roth CH Acquisition V Co. and Slacker Announce Expiration of Letter of Intent

Management

New Era Helium Corp. to List on NASDAQ Through Merger with Roth CH Acquisition V Co.

New Era Helium Corp. and Roth CH Acquisition V Co. announce the Filing of an Investor Presentation for the Proposed Business Combination

Roth CH Acquisition

Roth CH Acquisition V And New Era Helium (NEH) inked A Deal To Combine Business At A Pre-money Valuation Of $90M, Which Is Expected To Result In NEH Becoming A Public Company

Roth CH Acquisition V Co. (the "Company" or "ROCL") announced today that the exclusivity in its letter of intent with Slacker, Inc., LiveOne's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LVO#NASDAQ">LVO</a>) wholly owned subsidiary ("Slacker"), has expired and the parties have mutually agreed to terminate discussions with respect to a potential transaction to acquire Slacker. As a result, ROCL is currently exploring opportunities with other potential merger candidates in order to complete its business combination.This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Contracts

Roth CH Acquisition V Co. And Slacker Announce Expiration Of Letter Of Intent

Roth CH Acquisition V C Shares Halted;  Pending News

Deal Is Expected to Value Slacker at $160 Million Pre-MoneySlacker Surges to Over 3 Million Members Adding Over 225K Since January 1, 2023&#x2A;Byron Roth Expected to Remain on the Post-Merger Company's Board of Directors&nbsp;LOS ANGELES, CA , April 28, 2023 (GLOBE NEWSWIRE) -- via<a href="https://www.globenewswire.com/Tracker?data=-4dRC_CpfNe0bOpSlptv_EcN0WlWTc5PluNhMWFRsDDRUnRWPnlvmiuig-9UgT39qyMPu8-XDvobKgD9JezAVYEybvdyDFexuIaZLZHn9zA="> NewMediaWire</a>- LiveOne (Nasdaq:&nbsp;<a href="https://www.globenewswire.com/Tracker?data=W54P2fpmrL64mBy4TXXpb_x-f9eiFRuQ2jKPOHQQZT6KHI7A99jet4pOO8xn6AbGvNC_LzJGk2h2BG1yccAqEAJtEyWViu7-_60qpbWGqM-RJzvkHGOhE0rGMX45H9QvY-wXaDCHT0PpSOWVxqOujx5yOz_uTE1W1x6xWVIQ9Qp-P0hoY16xIwFPINF3iOkiXlfW14Zl7muAt4VbEZg9e6jORL9SoZW1GBtoIS3NTcmBKIG4phJDH6ZTAaMxstyHmfGwLmoKj1NJytFRxNZlqi1V2wraupd4LDaH9wcsg0Q=">LVO</a>), an award-winning, creator-first music, entertainment, and technology platform, and Roth CH Acquisition V Co. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROCL#NASDAQ">ROCL</a>, ROCLU, ROCLW))))), a special purpose acquisition company, announced today that they have entered into a letter of intent to merge LiveOne's wholly-owned subsidiary, Slacker, Inc., with Roth CH Acquisition V Co. at a pre money valuation of $160 million, subject to completion of diligence and definitive documentation.After the contemplated merger, LiveOne is expected to own the substantial majority of post-merger company and it is expected that Slacker will continue its existing business relationship with LiveOne and LiveOne's <a href="https://www.globenewswire.com/Tracker?data=vou-z8scpAXuYOPV4PkwJI1bKbMaGq3FhapxzIArVEeUx3lZAccoR3n9ucBK38zjsvvqdnu2uzrshdqQEeTyVw==">PodcastOne</a> in the creation and distribution of award-winning content. The parties currently anticipate being in a position to close the proposed merger in the fourth calendar quarter of 2023, subject to various conditions and approvals and completion of diligence and definitive documentation.Slacker Radio is a membership music streaming service that was launched in 2007 and is known for its personalized radio stations, expertly crafted by music experts and DJs, as well as its large music library which includes millions of songs across all genres. It also includes podcasts from PodcastOne, livestreamed video and on-demand programming, and livestreamed festivals, concerts, and pay-per-view ("PPV") events. Slacker currently has a paid and free ad-supported membership base of more than 3 million&#x2A;.Roth CH Acquisition V Co. is led by executives and affiliates of Roth Capital Partners and Craig-Hallum Capital Group, two leading small-cap growth investment banks.&nbsp;Subsequent to the closing of the proposed merger, Byron Roth, Co-Chairman and Co-CEO of Roth CH Acquisition V Co., currently plans to remain a member of the post-merger company's board of directors.Robert Ellin, Chairman and CEO of LiveOne and CEO of Slacker, commented, "We believe this combination will represent an exciting opportunity for Slacker to scale more rapidly its fast-growing music subscription service both geographically and through additional B-to-B white label agreements, particularly with automotive OEMs."Byron Roth stated, "We are enthused to enter into this agreement with Slacker and look forward to working with LiveOne to complete this merger. We believe the size and growth of the streaming music business makes this a compelling deal for our shareholders."&nbsp;&nbsp;&nbsp;The LOI is non-binding and the contemplated merger is subject to execution of definitive documentation, regulatory approval, approval of Roth CH Acquisition V Co.'s shareholders to extend the time for the company to consummate a business combination, approval of Roth CH Acquisition V Co.'s &nbsp;shareholders of the proposed merger with Slacker, and a minimum cash proceeds to be raised and/or retained by Roth CH Acquisition V Co. in connection with the closing of the proposed merger. There can be no assurance that LiveOne's and Roth CH Acquisition V Co.'s efforts will result in the consummation of the proposed merger.&nbsp;

LiveOne's Slacker And Roth CH Acquisition V Co. Announce Letter Of Intent To Merge; Deal Is Expected To Value Slacker At $160M Pre-Money

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Comments

Roth CH Acquisition

News

Latest news for Roth CH Acquisition (NASDAQ:ROCL) Stock

Thursday, January 04, 2024

Monday, October 30, 2023

Friday, April 28, 2023